By Lisa Raffensperger | March 13, 2013 1:22 pm Most people who live to old age will suffer from arthritis. The conditions prevalence is growing alongside a graying world population Continue reading
Tag Archives: a-gene-therapy
Mesothelioma Gene Therapy | 5 to Watch – Video
Mesothelioma Gene Therapy | 5 to Watch Gene therapy utilizes immune response to fight mesothelioma cancer. Either killing the meso directly, or making it more likely to be defeated by conventional treatments. Links to information about mesothelioma gene therapy: Weaponized Measles: www.youtube.com Listeria based Mesothelin Vaccine: By: personalinjurynews Continue reading
Researchers initiate first gene therapy clinical trial for Fabry disease
Researchers in Calgary have launched the first gene therapy clinical trial in the world for Fabry disease, a rare inherited enzyme deficiency that can shorten the lifespan of people who have it by as much as 40 years. Researchers will first remove a quantity of stem cells from a Fabry patient’s blood. Then a working copy of a new gene will be inserted into the stem cells using a specially engineered virus Continue reading
Canada launches first gene therapy trial for Fabry disease
Public release date: 24-Jan-2013 [ | E-mail | Share ] Contact: Gregory Harris gregory.harris@albertahealthservices.ca 403-619-3108 Alberta Health Services CALGARY Researchers in Calgary have launched the first gene therapy clinical trial in the world for Fabry disease, a rare inherited enzyme deficiency that can shorten the lifespan of people who have it by as much as 40 years. Researchers will first remove a quantity of stem cells from a Fabry patient’s blood. Continue reading
AAV-based gene therapy cocktail may help extend lives of children with Canavan disease
Results of a clinical trial that began in 2001 show that a gene therapy cocktail conveyed into the brain by a molecular special delivery vehicle may help extend the lives of children with Canavan disease, a rare and fatal neurodegenerative disorder. Continue reading
uniQure Initiates Phase I in Acute Intermittent Porphyria
AMSTERDAM, December 11, 2012 /PRNewswire/ — uniQure B.V., a leader in the field of human gene therapy, today announced the start of its Phase I clinical trial in acute intermittent porphyria (AIP) with the treatment of the first patient. Continue reading
Gene therapy shows promise in eradicating blood cancers
A 7-year-old pixie named Emily Whitehead has erased any remaining doubts about the power of a University of Pennsylvania gene therapy to eradicate certain blood cancers. Continue reading
University of Pennsylvania gene therapy shows promise in eradicating some blood cancers
A 7-year-old pixie named Emily Whitehead has erased any remaining doubts about the power of a University of Pennsylvania gene therapy to eradicate certain blood cancers. Continue reading
Gene Therapy on the Mend as First Treatment Gets Approval
The first regulatory approval of a gene therapy treatment could spark broader patient access to the technology. Last month, Europe’s Committee for Medicinal Products for Human Use approved a gene therapy for a rare genetic disease, the first time a Western regulatory agency has okayed such a treatment, though gene therapies have been approved in China. Continue reading
Gene Therapy on the Mend as Treatment Gets Western Approval
Regulatory approval of a gene therapy treatment in Europe could spark broader patient access to the technology. Continue reading
uniQure Appoints Hans Christian Rohde Chief Commercial Officer
AMSTERDAM, The Netherlands, December 6, 2012 /PRNewswire/ — uniQure B.V., a leader in the field of human gene therapy, today announced the appointment of Hans Christian Rohde as Chief Commercial Officer. Mr. Rohde joins uniQure from Basilea Pharmaceutica (SIX:BSLN) where from 2007 he was Chief Commercial Officer and member of the company’s executive management committee with responsibility for global commercial operations, marketing, supply chain, medical affairs, pricing and market access. Continue reading
European Union's First Gene Therapy Approval Represents Major Advancement For Industry
SAN DIEGO, Nov. Continue reading
European Union Approves New Gene Therapy Drug
November 2, 2012 Lee Rannals for redOrbit.com Your Universe Online A drug that has the ability to correct errors in a genetic code has been approved for the first time ever in Europe. The European Commission has given Glybera authorization to sell the drug next summer for treating an ultra rare genetic disease. The small Dutch biotech companys drug will cost around $1.6 million per patient, a new record price for medicine Continue reading
bluebird bio is awarded $9.3m to support its gene therapy treatments
By Chris Reidy, Globe Staff bluebird bio, a Cambridge company that eschews capital letters, said in a Friday press release that the California Institute for Regenerative Medicine has approved a $9.3 million award to support the development one of bluebird bios gene therapies. Continue reading
Gene therapy regimen can safely restore immune systems to children with Bubble Boy disease
UCLA stem cell researchers have found that a gene therapy regimen can safely restore immune systems to children with so-called “Bubble Boy” disease, a life threatening condition that if left untreated can be fatal within one to two years. In the 11-year study, researchers were able to test two therapy regimens for 10 children with ADA-deficient severe combined immunodeficiency (SCID). Continue reading
'Bubble babies' immune systems restored
LOS ANGELES UCLA stem cell researchers have found that a gene therapy regimen can safely restore immune systems to children with so-called “bubble boy” disease, a life-threatening condition that if left untreated can be fatal within one to two years. Continue reading
UCLA stem cell researchers use gene therapy to restore immune systems in 'bubble babies'
Public release date: 11-Sep-2012 [ | E-mail | Share ] Contact: Kim Irwin kirwin@mednet.ucla.edu 310-435-9457 University of California – Los Angeles Health Sciences UCLA stem cell researchers have found that a gene therapy regimen can safely restore immune systems to children with so-called “Bubble Boy” disease, a life threatening condition that if left untreated can be fatal within one to two years. In the 11-year study, researchers were able to test two therapy regimens for 10 children with ADA-deficient severe combined immunodeficiency (SCID) Continue reading
Research and Markets: Gene Therapy – Technologies, Markets and Companies – Updated 2012 Report
DUBLIN–(BUSINESS WIRE)– Research and Markets (http://www.researchandmarkets.com/research/96czlk/gene_therapy_tec) has announced the addition of Jain PharmaBiotech’s new report “Gene Therapy – Technologies, Markets and Companies” to their offering. Continue reading
Company Aims to Cure Blindness with Optogenetics
The technique would retrain cells that typically don’t respond to light. Continue reading
Europe Takes The Lead Toward Approval Of First Gene Therapy Drug
VideoIt's taken decades of work but the first gene therapy is on the verge of finally getting approval in Europe. A watershed moment in gene therapy has finally come to pass. Continue reading